Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $9.50.

A number of research analysts have recently commented on XERS shares. Oppenheimer restated an “outperform” rating and issued a $18.00 target price on shares of Xeris Biopharma in a research note on Friday, November 7th. Barclays assumed coverage on Xeris Biopharma in a report on Monday, December 8th. They issued an “overweight” rating and a $9.00 price objective for the company. Piper Sandler boosted their target price on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Zacks Research lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, October 8th.

Xeris Biopharma Trading Down 2.0%

NASDAQ:XERS opened at $7.71 on Wednesday. The company has a 50-day moving average price of $7.28 and a 200-day moving average price of $7.24. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -77.09 and a beta of 0.50. Xeris Biopharma has a 12 month low of $3.14 and a 12 month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The company had revenue of $74.38 million for the quarter, compared to the consensus estimate of $74.19 million. Equities analysts forecast that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $7.43, for a total value of $123,835.81. Following the sale, the insider directly owned 1,308,103 shares of the company’s stock, valued at approximately $9,719,205.29. The trade was a 1.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John Patrick Shannon, Jr. sold 24,907 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $7.08, for a total value of $176,341.56. Following the transaction, the insider owned 2,705,346 shares of the company’s stock, valued at $19,153,849.68. The trade was a 0.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 263,550 shares of company stock worth $1,917,672. Company insiders own 4.56% of the company’s stock.

Institutional Trading of Xeris Biopharma

Institutional investors have recently bought and sold shares of the company. Calamos Advisors LLC bought a new stake in shares of Xeris Biopharma in the third quarter worth approximately $1,116,000. Voya Investment Management LLC lifted its position in Xeris Biopharma by 866.6% during the third quarter. Voya Investment Management LLC now owns 400,079 shares of the company’s stock valued at $3,257,000 after purchasing an additional 358,689 shares during the period. Squarepoint Ops LLC boosted its holdings in Xeris Biopharma by 1,679.1% in the second quarter. Squarepoint Ops LLC now owns 284,567 shares of the company’s stock worth $1,329,000 after purchasing an additional 268,572 shares during the last quarter. Savvy Advisors Inc. bought a new stake in Xeris Biopharma in the 2nd quarter worth approximately $189,000. Finally, Corient Private Wealth LLC bought a new stake in Xeris Biopharma in the 2nd quarter worth approximately $320,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.